Related Experiment Video
Updated: Apr 16, 2026
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
17.1K
Clinical proteomics and breast cancer
Bashar A Zeidan1, Paul A Townsend2, Spiros D Garbis1
1Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton University Hospitals NHS Foundation Trust, Southampton, SO16 6YD, UK.
Summary
Clinical proteomics offers new ways to diagnose, stratify, and treat breast cancer. This review covers recent discoveries and future potential for personalized medicine and improved patient outcomes.
Area of Science:
- Biomedical research
- Oncology
- Proteomics
Background:
- Breast cancer is a complex, heterogeneous disease with many unknown molecular mechanisms.
- Advances in biomedical research are crucial for discovering novel molecular players in cancer.
- Clinical proteomics technologies are rapidly evolving, promising advancements in breast cancer management.
Purpose of the Study:
- To review recent literature on clinical proteomics in breast cancer research.
- To highlight the principles, advantages, limitations, discoveries, and future prospects of clinical proteomics in this field.
Main Methods:
- Literature review of recent studies.
- Analysis of clinical proteomics applications in breast cancer.
Main Results:
- Proteomic studies aim to develop personalized therapies for breast cancer.
- Research is increasing understanding of post-treatment relapse and improving patient prognosis prediction.
- Identification of potential subtype-refining profiles and novel diagnostic/prognostic biomarkers.
Conclusions:
- Clinical proteomics has identified potential biomarkers for breast cancer diagnosis and prognosis.
- Proteomic discoveries aid in refining breast cancer subtypes and developing personalized treatment strategies.
- Future prospects include enhanced early diagnosis, stratification, and treatment response prediction.
